An Open Label, Dose Comparison Study to Assess the Efficacy of MBM-02 (Tempol) as a Treatment for Patients Diagnosed With Prostate Cancer in Biochemical Recurrence
Latest Information Update: 08 May 2023
At a glance
- Drugs Tempol (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Sponsors Matrix Biomed
Most Recent Events
- 12 May 2021 New trial record